COMPANY UPDATES
02
May
2018
Novoheart to Debut New, State-of-the-art ‘Human Heart-in-a-Jar 2.0’ Technology at the 2018 International Society for Stem Cell Research (ISSCR) Annual Meeting

Novoheart  announced that the next generation of its ‘Human heart-in-a-jar’ technology - which makes up a key component of its comprehensive MyHeartTM Platform - will be unveiled for the first time at the Annual Meeting of the International Society for Stem Cell Research (ISSCR), held in Melbourne, Australia from 20-23 June, 2018. The Annual Meeting is the flagship event of the professional society, where cutting-edge stem cell research will be presented to over 4,000 attendees which include notable scientists, innovators, industry representatives and media.

The first-generation, fluid-ejecting, three-dimensional ‘Human heart-in-a-jar’ is the only technology on the market to date that enables the clinically informative assessment of human cardiac pump performance, such as cardiac output and ejection fraction, which no other engineered heart tissues on the market are capable of. Dr. Kevin Costa, CSO of Novoheart, will present to the attendees of the ISSCR Annual Meeting the new Human heart-in-a-jar 2.0, demonstrating its ability to deliver a >200-fold increase in efficiency, throughput, sensitivity and accuracy, compared to the first generation. This marked enhancement is achieved through a combination of custom-designed hardware and software developed to complement the best-in-class hvCOC biological construct.

For the detailed press release, please click here.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!